中华医学杂志
2023年 · 第103卷第42期
中华医学杂志
- 全部
- 述评
- 专家论坛
- 标准与规范
- 肿瘤心脏病学
- 临床研究
- 病例报告
- 综述
- 文献速览
- 更正
Osteosarcoma and Ewing's sarcoma are common clinical malignant bone tumors, and their onset age is frequent<30 years old, the main treatment mode was surgery combined with systemic chemotherapy, and the chemotherapy regimen included high-dose anthracyclines. Observing the occurrence of anthracycline-related heart failure in such patients is helpful for people to find out the objective law of this type of cardiotoxicity, and it is helpful to improve its prevention and treatment level.
Three factors, such as clinical characteristics of tumor patients, tumor stage, and anti-tumor therapy (especially anti-vascular endothelial growth factor antibodies such as bevacizumab and tyrosine kinase inhibitors), can cause endothelial cell dysfunction and hypercoagulability, which increases the risk of arterial thrombotic events (ATE) in tumor patients. Although the use of low molecular weight heparin for the treatment of venous thromboembolism (VTE) has been shown to be safe and effective in ambulatory tumor patients, whether anticoagulant therapy is equally beneficial for the prevention of ATE is unclear.
Anthracyclines can lead to dose-related myocardial damage and tumor treatment-related cardiac insufficiency (CTRCD) while improving survival for multiple cancers. Cardiac CARE is a multicenter, prospective, randomized, open, blinded endpoint clinical trial to observe whether carvedilol and candesartan combination therapy guided by high-sensitivity troponin can prevent left ventricular dysfunction in patients at high risk for CTRCD during anthracycline chemotherapy.
Article "Clinical Practice Guidelines for Transarterial Chemoembolization (TACE) Treatment of Hepatocellular Carcinoma in China (2023 Edition)", Vol. 103, No. 34, 2023, Chinese Journal of Medicine, Page 2679 "Recommended angiographic validation at least 5 min after the end of embolization to accurately assess the efficacy of embolization (Evidence Level 1, Recommended Strength A)", "Evidence Level 1" here should be "Evidence Level 5", and the 59th reference here should be "de Baere T, Arai Y, Lencioni R, et al. Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion [J]. Cardiovasc Intervent Radiol, 2016, 39 (3): 334-343. DOI: 10.1007/s00270-015-1208-y. "; The reviewing expert "Jin Guiyun (Hainan Provincial People's Hospital)" should be "Jin Guiyun (the First Affiliated Hospital of Hainan Medical College)"; Page 2682 "Carrelizumab" shall be "Carrelizumab". Corrections are hereby made.
本期目次
